QuellTX Logo
06/01/22

Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, UK and BOSTON, MA – January 6, 2022 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Tuesday, January 11, 2022 at 12:00 pm ET.

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for stability, persistence and potency than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.

Contacts

Luke Henry, Chief Business Officer

Quell Therapeutics

IR@quell-tx.com

Media: Mark Swallow, Frazer Hall, Eleanor Perkin

MEDiSTRAVA Consulting

+44 203 928 6900

Quell-Tx@Medistrava.com

Investors: Christina Tartaglia

Stern Investor Relations, Inc.

+1 212 362 1200

christina@sternir.com

06/01/22

Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, UK and BOSTON, MA – January 6, 2022 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More
29/11/21

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focused investors - Proceeds to be used…...

Read More
22/11/21

Quell Therapeutics Announces Participation in Upcoming Investor Conferences

London, UK and Boston, MA – November 22, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More